5 GLP-1 receptor agonists: a multi-functional therapeutic targeting metabolic dysfunction Glucagon-like peptide-1 (GLP-1), a multifaceted hormone expressed primarily in the intestines and pancreas, mediates physiological and behavioral properties through its receptor, GLP-1 receptors (GLP-1R)
Liver Function Support: Its ability to inhibit glucagon release results in decreased hepatic glucose production, a feature that is integral for maintaining stable blood sugar levels
GLP-1 medications work by mimicking the bodys natural GLP-1 hormones that regulate blood sugar, insulin release, digestion, and appetite
Notably, in June 2021, the FDA approved semaglutide for chronic weight management in adults dealing with general obesity or overweight and presenting at least one weight-related condition [Reference Davies, Faerch, Jeppesen, Pakseresht, Pedersen and Perreault45]
Remarkably, there is evidence that GLP-1 agonists can enhance left ventricular ejection fraction, inotropy, coronary blood flow, cardiac output, and vascular endothelial function because of their cardiovascular effects and decrease overall cardiovascular event risks
PlexusDx's Precision Peptide Genetic Test ($99) identifies variants in genes controlling lipid metabolism, including GIPR, GLP1R, and other cholesterol-related pathways